Skip to main content
. 2019 Aug 5;132(15):1765–1772. doi: 10.1097/CM9.0000000000000341

Figure 1.

Figure 1

The cumulative incidences of NRM, relapse, PFS, and OS in the MRD group and haplo group. (A) NRM in patients with MM or PCL receiving haploidentical SCT (n = 27) vs. MRD transplantation (n = 70). (B) Relapse in patients with MM or PCL receiving haploidentical SCT (n = 27) vs. MRD transplantation (n = 70). (C) PFS in patients with MM or PCL receiving haploidentical SCT (n = 27) vs. MRD transplantation (n = 70). (D) OS in patients with MM or PCL receiving haploidentical SCT (n = 27) vs. MRD transplantation (n = 70). MM: Multiple myeloma; MRD: Matched-related donor; NRM: Non-relapse mortality; PCL: Plasma cell leukemia; PFS: Progression-free survival; OS: Overall survival; SCT: Stem-cell transplantation.